TRAIL is a promising drug candidate for the treatment of many cancers.The investigation of TRAIL-based therapy in clinical trials focuses on recombinantTRAIL proteins and anti-TRAIL antibodies, but delivery and drug resistance issuesare the main hurdles in the successful translation of these results. Here, TNFSF10 is linked to cancer.